We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cristal Therapeutics and PX Biosolutions Collaborate
News

Cristal Therapeutics and PX Biosolutions Collaborate

Cristal Therapeutics and PX Biosolutions Collaborate
News

Cristal Therapeutics and PX Biosolutions Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cristal Therapeutics and PX Biosolutions Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cristal Therapeutics has announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology CriVac® for the design of innovative vaccines.

The CriVac® platform enables the tailor-made development of well-characterized polymeric nanoparticles of a specific size, that allow optimal antigen presentation to dendritic cells. CriVac® is one of the proprietary nanotechnology platforms of Cristal Therapeutics, next to CriPec®.

PX Biosolutions is an Australian based company operating from Melbourne, Victoria. PX Biosolutions’ scientists have developed DCtag™ vaccine formulations against various types of cancer. These vaccine formulations have been tested successfully in animal models.

Joost Holthuis, CEO of Cristal Therapeutics says: “We are very excited about this collaboration that fits our strategy to set up product developments with companies active in the vaccine area. We are convinced that we can create additional value for patients and vaccine companies by development of superior vaccine products based on our CriVac® technology”.

Ann Meulemans, CEO of PX Biosolutions comments: “Our team is very enthusiastic about the possibility to enhance the flexibility of its DCtag™ platform by using the CriVac technology.”

Advertisement